accelerated approval, aducanumab, aduhelm, Alzheimer’s disease, alzheimers disease in african americans, amyloid beta, apolipoprotein e, biogen, donanemab, eisai, eli lilly, Food and Drug Administration, health medical pharma, lecanemab, leqembi, monoclonal antibodies, Tech Industry, Tech News, teresa buracchio
In a First, FDA Grants Full Approval to Anti-Amyloid Drug for Alzheimer’s
On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies …
